+91 40 6815 7077 [email protected]

In today's world, it is not possible for any entity to work independently. We need strategic business partner to grow further where we can share the services to provide full spectrum. We, Abiogenesis believe that everyone has their own core strength and to make clinical development faster, we need to create synergy by doing business collaboration. We work with following partners to provide the services in different area of clinical development and different geographic.

EP Group

EP Group is a consulting agency based in the heart of the Russian Federation, Moscow. Abiogenesis and EP Group are working together for many years and now join the strategic partnership. All the studies in Asia pack of EP Group will be executed by Abiogenesis and Abiogenesis Studies where sites need in Russian Federation will be managed by EP Group. EP Group have been providing a full package of services to multinational pharmaceutical companies since 2008 and has accumulated an extensive experience in assisting different types of businesses to live up to all their company’s expectations. EP Group offer a wide range of services in Product Launch, Product Management, Regulatory Strategy and all kinds of Clinical Studies. All staff of EP Group highly experienced, skilled and technically competent that allows them to challenge the most sophisticated issues.

Scitus Pharma

Scitus Pharma Services Private Limited is an organization intending to provide services to the pharmaceutical and biopharmaceutical industries for bioavailability and bioequivalence studies. Abiogenesis and Scitus Pharma Services Private Limited are working together from many year and now join the strategic partnership for supporting each other on clinical and bioavailability and bioequivalence studies. All the studies for Clinical Trials from Phase I to Phase IV will be executed by Abiogenesis and BA/BE and PK/PD part of study will be manage by Scitus Pharma Services Private Limited. The Scitus Pharma facility has established state-of-the art IT infrastructure that is fully compliant with US FDA 21CFR11 requirements and also has pooled together scientists who have worked in reputed CROs and pharmaceutical companies in their previous assignments.